The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients

References

• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.
   PubMed Web of Science ®Google Scholar
• Grayson M. Bladder cancer. Nature. 2017;551(7679):S33.
   PubMed Web of Science ®Google Scholar
• Roh YG, Mun MH, Jeong MS, et al. Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1. BMB Rep. 2018;51(2):98–103.
   PubMed Web of Science ®Google Scholar
• Long X, Xiong W, Zeng X, et al. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERbeta/Bcl-2 signalling. Cell Death Dis. 2019;10(5):375.
   PubMedGoogle Scholar
• Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3ʹUTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4(1):10.
   PubMed Web of Science ®Google Scholar
• H S, J W, C H. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74(4):640–650.
   PubMed Web of Science ®Google Scholar
• Zaccara S, Ries R, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–624.
   PubMed Web of Science ®Google Scholar
• Y P, P M, Y L, et al. Multiple functions of mA RNA methylation in cancer. J Hematol Oncol. 2018;11(1):48.
   PubMedGoogle Scholar
• S T, W R, M L. The role of m6A RNA methylation in cancer. Biomed Pharmacothe. 2019;112:108613.
   PubMed Web of Science ®Google Scholar
• Chen J, Du B. Novel positioning from obesity to cancer: FTO, an m(6)A RNA demethylase, regulates tumour progression. J Cancer Res Clin Oncol. 2019;145(1):19–29.
   PubMed Web of Science ®Google Scholar
• Wen L, Pan X, Yu Y, et al. Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity. BMC Urol. 2020;20(1):39.
   PubMed Web of Science ®Google Scholar
• Tao L, Mu X, Chen H, et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 2021;11(2):e310.
   PubMed Web of Science ®Google Scholar
• Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206.
   PubMed Web of Science ®Google Scholar
• Meyer KD, Patil DP, Zhou J, et al. 5ʹ UTR m(6)A Promotes Cap-Independent Translation. Cell. 2015;163(4):999–1010.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018;172(1–2):90–105 e23.
   PubMed Web of Science ®Google Scholar
• Shima H, Matsumoto M, Ishigami Y, et al. S-Adenosylmethionine Synthesis Is Regulated by Selective N(6)-Adenosine Methylation and mRNA Degradation Involving METTL16 and YTHDC1. Cell Rep. 2017;21(12):3354–3363.
   PubMed Web of Science ®Google Scholar
• Nagarajan A, Janostiak R, Wajapeyee N. Dot Blot Analysis for Measuring Global N(6)-Methyladenosine Modification of RNA. Methods Mol Biol. 2019;1870:263–271.
   PubMedGoogle Scholar
• Takayama KI, Suzuki T, Fujimura T, et al. Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proceedings of the National Academy of Sciences of the United States of America 2017; 114:10461–10466.
   Google Scholar
• Song H, Wang Y, Wang R, et al. SFPQ Is an FTO-Binding Protein that Facilitates the Demethylation Substrate Preference. Cell Chem Biol. 2020;27(3):283–91 e6.
   PubMed Web of Science ®Google Scholar
• Yu H, Yang X, Tang J, et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2alpha-Mediated Glycolysis. Mol Ther Nucleic Acids. 2021;23:27–41.
   PubMedGoogle Scholar
• Jin H, Ying X, Que B, et al. N(6)-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine. 2019;47:195–207.
   PubMed Web of Science ®Google Scholar
• Gu C, Wang Z, Zhou N, et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1. Mol Cancer. 2019;18(1):168.
   PubMed Web of Science ®Google Scholar
• Luo H, Xu C, Le W, et al. lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. J Cell Biochem. 2019;120(8):13487–13493.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Ma Q, Zhuang C, et al. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. FASEB J. 2019;33(10):11045–11059.
   PubMed Web of Science ®Google Scholar
• Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887.
   PubMed Web of Science ®Google Scholar
• Geng Y, Guan R, Hong W, et al. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Ann Transl Med. 2020;8(6):387.
   PubMed Web of Science ®Google Scholar
• Li G, Chen Q, Wang L, et al. Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls. Tumour Biol. 2012;33(4):1237–1243.
   PubMedGoogle Scholar
• Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Mol Carcinog. 2018;57(5):590–597.
   PubMed Web of Science ®Google Scholar
• Xu D, Shao W, Jiang Y, et al. FTO expression is associated with the occurrence of gastric cancer and prognosis. Oncol Rep. 2017;38(4):2285–2292.
   PubMed Web of Science ®Google Scholar
• Song W, Yang K, Luo J, et al. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression. Aging (Albany NY). 2021;13(3):3909–3925.
   PubMedGoogle Scholar
• Lim YW, James D, Huang J, et al. The Emerging Role of the RNA-Binding Protein SFPQ in Neuronal Function and neurodegeneration. Int J Mol Sci. 2020;21(19):21.
   PubMed Web of Science ®Google Scholar